Gamze Uğurluer1, Sinan Yavuz2, Züleyha Çalıkuşu3, Ertuğrul Seyrek4, Mustafa Kibar5, Meltem Serin1, Canan Ersöz6, Orhan Demircan7. 1. Department of Radiation Oncology, Acıbadem University School of Medicine Acıbadem Adana Hospital, Adana, Turkey. 2. Department of Internal Medicine, Acıbadem University School of Medicine Acıbadem Adana Hospital, Adana, Turkey. 3. Clinic of Medical Oncology, Acıbadem University School of Medicine Acıbadem Adana Hospital, Adana, Turkey. 4. Clinic of Medical Oncology, Acıbadem Adana Hospital, Adana, Turkey. 5. Clinic of Nuclear Medicine, Acıbadem Adana Hospital, Adana, Turkey; Department of Nuclear Medicine, Çukurova University School of Medicine, Adana, Turkey. 6. Clinic of Pathology, Acıbadem Adana Hospital, Adana, Turkey. 7. Clinic of General Surgery, Acıbadem Adana Hospital, Adana, Turkey.
Abstract
OBJECTIVE: In this study, we aimed to determine the correlation between pretreatment-staging 18F-FDG total body positron-emission tomography/computed tomography (PET/CT) maximum standardized uptake value (SUVmax) levels and histopathologic and immunohistochemical predictive and prognostic factors in patients with breast cancer. MATERIALS AND METHODS: One hundred thirty-nine women with breast cancer who were treated between 2009 and 2015 at our hospital and who had pretreatment-staging PET/CT were included in the study. SUVmax levels and histopathologic and immunohistochemical results were compared. RESULTS: The median age was 48 years (range, 29-79 years). The mean tumor diameter was 33.4 mm (range, 7-120 mm). The histology was invasive ductal carcinoma in 80.6% of the patients. In the univariate analysis, SUVmax levels were significantly higher in patients with invasive ductal carcinoma; in patients with a maximum tumor diameter more than 2 cm; patients who were estrogen, progesterone, and combined hormone receptor-negative, triple-negative patients, and in tumors with higher grades (p<0.05). In HER2-positive patients, SUVmax levels were higher even if it was not statistically significant. There was no correlation between lymph node metastases and pathologic stage. In multivariate analysis, tumor diameter was an independent factor. CONCLUSION: SUVmax levels are correlated with known histopathologic and immunohistochemical prognostic factors. PET/CT could be useful in preoperative evaluation of patients with breast cancer to predict biologic characteristics of tumors and prognosis.
OBJECTIVE: In this study, we aimed to determine the correlation between pretreatment-staging 18F-FDG total body positron-emission tomography/computed tomography (PET/CT) maximum standardized uptake value (SUVmax) levels and histopathologic and immunohistochemical predictive and prognostic factors in patients with breast cancer. MATERIALS AND METHODS: One hundred thirty-nine women with breast cancer who were treated between 2009 and 2015 at our hospital and who had pretreatment-staging PET/CT were included in the study. SUVmax levels and histopathologic and immunohistochemical results were compared. RESULTS: The median age was 48 years (range, 29-79 years). The mean tumor diameter was 33.4 mm (range, 7-120 mm). The histology was invasive ductal carcinoma in 80.6% of the patients. In the univariate analysis, SUVmax levels were significantly higher in patients with invasive ductal carcinoma; in patients with a maximum tumor diameter more than 2 cm; patients who were estrogen, progesterone, and combined hormone receptor-negative, triple-negative patients, and in tumors with higher grades (p<0.05). In HER2-positive patients, SUVmax levels were higher even if it was not statistically significant. There was no correlation between lymph node metastases and pathologic stage. In multivariate analysis, tumor diameter was an independent factor. CONCLUSION: SUVmax levels are correlated with known histopathologic and immunohistochemical prognostic factors. PET/CT could be useful in preoperative evaluation of patients with breast cancer to predict biologic characteristics of tumors and prognosis.
Entities:
Keywords:
18F-FDG; Breast cancer; positron-emission tomography; predictive; prognosis
Authors: Therese B Bevers; Benjamin O Anderson; Ermelinda Bonaccio; Patrick I Borgen; Saundra Buys; Mary B Daly; Peter J Dempsey; William B Farrar; Irving Fleming; Judy E Garber; Randall E Harris; Mark Helvie; Susan Hoover; Helen Krontiras; Sara Shaw; Eva Singletary; Celette Sugg Skinner; Mary Lou Smith; Theodore N Tsangaris; Elizabeth L Wiley; Cheryl Williams Journal: J Natl Compr Canc Netw Date: 2006-05 Impact factor: 11.908
Authors: C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein Journal: Nature Date: 2000-08-17 Impact factor: 49.962
Authors: A J Nixon; D Neuberg; D F Hayes; R Gelman; J L Connolly; S Schnitt; A Abner; A Recht; F Vicini; J R Harris Journal: J Clin Oncol Date: 1994-05 Impact factor: 44.544
Authors: Mathias K Fehr; Rene Hornung; Zsuzsanna Varga; Daniel Burger; Thomas Hess; Urs Haller; Daniel Fink; Gustav K von Schulthess; Hans C Steinert Journal: Breast J Date: 2004 Mar-Apr Impact factor: 2.431
Authors: A Goldhirsch; E P Winer; A S Coates; R D Gelber; M Piccart-Gebhart; B Thürlimann; H-J Senn Journal: Ann Oncol Date: 2013-08-04 Impact factor: 32.976
Authors: Tian Du; Li Zhu; Kevin M Levine; Nilgun Tasdemir; Adrian V Lee; Dario A A Vignali; Bennett Van Houten; George C Tseng; Steffi Oesterreich Journal: Sci Rep Date: 2018-05-08 Impact factor: 4.379